Castlight Health, a provider of health care transparency solutions for employers and payers, has appointed John Driscoll as president. Castlight Health is headquartered in San Francisco and backed by investors including Allen & Company, Cleveland Clinic, Maverick Capital, Morgan Stanley Investment Management, Oak Investment Partners, Redmile Group, T. Rowe Price, U.S. Venture Partners, Venrock, Wellcome [...]
You are browsing the archive for Maverick Capital - peHUB.
Uptake Medical has closed a Series C funding round. The round was led by Singapore-based Crescent Point Group, with existing investors, Maverick Capital, ONSET Ventures, GBS Venture Partners, WRF Capital, Arboretum Ventures and Affinity Capital, making additional investments. Uptake Medical is focused on the development and commercialization of innovative, non-surgical treatments for lung diseases. PRESS [...]
San Francisco-based Kontagent, a maker of enterprise user analytics technology, has raised $12 million in Series B financing. Battery Ventures led the round. Maverick Capital and Altos Ventures also participated. Roger Lee, a general partner at Battery Ventures, will join Kontagent’s board.
SeeChange, the health management and healthcare company, has accepted $20 million from new investor Maverick Capital and existing investor Psilos Group. Eric Kim worked on the investment from Maverick and Al Waxman, from Psilos, worked on the transactions. Other specifics were not publicized.
With investments increasing and time until liquidity lengthening to over eight years, medical device venture capitalists are pinning their hopes on a renewed IPO market. But they should be careful what they wish for. IPOs are not coming to the rescue today, nor have they ever been a panacea for VC’s who are deep into [...]
Bloomington, Indiana-based ProCure Treatment Centers has raised $40 million in private equity financing led by Maverick Capital. The funding will help ProCure develop and expand its network of proton therapy centers. Proton therapy is a form of radiation treatment and an alternative to standard X-ray radiation for patients with cancer and for some non-cancerous tumors. Previously, ProCure had raised more than $70 million from investors including McClendon Venture Company.
XenoPort Inc. (Nasdaq: XNPT) has agreed to sell $40 million worth of common stock and warrants via a registered direct offering. Maverick Capital is leading the deal, with Venrock also participating. Both firms have previously bought and sold XenoPort shares, including Venrock as an early-stage backer.